|Bid||53.13 x 800|
|Ask||53.53 x 800|
|Day's Range||52.33 - 55.96|
|52 Week Range||52.33 - 142.62|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||174.20|
Subscribe to Yahoo Finance Plus to view Fair Value for MDGLLearn more
CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer. “We are pleased to welcome Dr. Labriola to Madrigal at this pivotal time for the company,” said Becky Taub, M.D., President R&D and CMO of Madrigal. “With 35 years of experienc
Philadelphia-area life sciences news this week includes updates on a company seeking a patent for its Covid-19 therapy, a private stock sale, and a Temple University spinout publishing its study findings on a potential treatment for NASH.
Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.